Quantum BioPharma announced that on March 31, it has entered into a joint clinical study with Massachusetts General Hospital scientists to validate a novel positron emission tomography imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Secures Final Tranche of $5 Million Financing
- Quantum closes final C$2.42M tranche of C$5M total financing
- Quantum BioPharma reports FY24 net loss $14.9M vs. $18.2M last year
- Quantum BioPharma Reports Strong 2024 Financials and Advances in Clinical Trials
- Quantum BioPharma Strengthens Board with Terry Lynch Appointment